In a Phase 3 trial, the oral drug daraxonrasib roughly doubled median survival in previously treated metastatic pancreatic cancer — 13.2 months versus 6.7 on chemotherapy. Why the first RAS inhibitor to work here is a genuine turning point.
Health news explainer.
Pancreatic cancer has earned its grim reputation honestly. It is often found late, it resists most treatments, and for patients whose disease has spread and then progressed after first-line chemotherapy, the options have been few and the outlook measured in months. So when a once-daily pill roughly doubles how long those patients live, oncologists take notice — and that is exactly what a large trial reported in 2026.
What the trial showed
The drug is daraxonrasib, an oral therapy from Revolution Medicines that targets RAS, the mutated protein that drives the overwhelming majority of pancreatic cancers and has famously frustrated drug developers for decades. In the Phase 3 RASolute 302 trial, roughly 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma were randomized to daraxonrasib or the physician’s choice of standard chemotherapy.
The results, presented at a plenary session of the 2026 American Society of Clinical Oncology meeting and described by Dana-Farber Cancer Institute as a doubling of median overall survival, showed patients on the drug lived a median of 13.2 months versus 6.7 months on chemotherapy — a hazard ratio of 0.40. In a disease where incremental gains are the norm, a result of that size is, in the words of the researchers, unprecedented.
Why RAS matters
For non-specialists, the significance is easier to grasp through the target. RAS mutations power most pancreatic cancers, yet the protein was long considered “undruggable” — its surface offered nowhere for a drug to grab hold. Daraxonrasib belongs to a newer class designed to inhibit the active form of RAS directly. Being the first RAS inhibitor to extend survival in this setting, as the Pancreatic Cancer Action Network notes, is what makes this more than another incremental drug — it validates a target that has defeated the field for forty years.
Where it stands with regulators
Daraxonrasib is not yet a routine prescription, but it is moving quickly. Regulators granted it Breakthrough Therapy and Orphan Drug designations for previously treated metastatic disease with G12 mutations, and the company has said the drug was selected for a national priority review pilot intended to speed therapies aligned with public-health priorities. In May 2026, the FDA permitted an expanded-access program, letting some eligible patients receive the drug before full approval. The trial investigators have framed the data as support for a new standard of care in the second-line setting.
The honest caveats
Two things are worth keeping in perspective. First, “doubling survival” here means moving a median from about seven months to about thirteen — a genuine, meaningful gain for patients and families, but not yet a cure, and individual results vary. Second, the benefit was measured in patients whose tumors carry the specific RAS mutations the drug targets; it is not a therapy for everyone, and biomarker testing determines who is a candidate. Longer follow-up, real-world use, side-effect management, and eventual pricing and access will all shape how much this changes day-to-day care.
Why it matters anyway
Even with the caveats, this is the kind of result that resets expectations. Pancreatic cancer research has been a graveyard of promising ideas; a drug that clearly extends life in a rigorous Phase 3 trial, by hitting the mutation at the disease’s core, gives both patients and researchers something they have rarely had here — momentum. If the follow-on trials in earlier disease settings hold up, the more hopeful story is not just a better second-line option, but the beginning of RAS-targeted therapy reshaping how one of medicine’s hardest cancers is treated.
This article summarizes reported trial results and is for general information, not medical advice. Anyone facing a diagnosis should discuss options, eligibility, and clinical trials with their oncology team. Sources are linked above.
